The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In
particular, the indications for resection of branch duct IPMN have changed from early …

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are
lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of …

Pancreatic cysts are very common with the majority incidentally identified. There are several
types of pancreatic cysts; some types can contain cancer or have malignant potential …

Objective DNA-based testing of pancreatic cyst fluid (PCF) is a useful adjunct to the
evaluation of pancreatic cysts (PCs). Mutations in KRAS/GNAS are highly specific for …

Due to its poor prognosis and the late stage at which it is typically diagnosed, early detection
of pancreatic cancer is a pressing clinical problem. Advances in genomic analysis of human …

Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that
include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic …

Background & Aims Next-generation sequencing (NGS) of pancreatic cyst fluid is a useful
adjunct in the assessment of patients with pancreatic cyst. However, previous studies have …

Pancreatic cystic lesions are an increasingly common clinical finding. They represent a
heterogeneous group of lesions that include two of the three known precursors of pancreatic …

Background and Aims Currently, 3 guidelines are available for the management of
pancreatic cysts. These guidelines vary in their indication for resection of high-risk cysts. We …